La cadena de opciones muestra datos clave de las opciones de acciones de Arhaus a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Arhaus..

Arhaus (NASDAQ:ARHS) Bolsa, Cadena de Opciones

Arhaus

Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.

Acciones que se mueven

ARHS

BASE

CAPR

CDNA

CTOR

DGLY

HLMN

ICCT

NTHI

TILE

Xos sorprende al mercado con sólidos resultados en 2024 y hace subir sus acciones antes de la apertura. Descubre más movimientos aquí.

Acciones de Xos (XOS) suben alrededor de un 9%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Arhaus Inc

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.62 by 20.97 percent. This is a 47.06 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $685.68 million which beat the analyst consensus estimate of $680.51 million by 0.76 percent. This is a 14.31 percent increase over sales of $599.82 million the same period last year.

Earnings

Earnings Beats

News

Teradyne Q1 Adj. EPS $0.75 Beats $0.62 Estimate, Sales $685.68M Beat $680.51M Estimate

Transocean, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/g45052677/transocean-ltd-reports-first-quarter-2025-results"> from the report. </a>
The Details: Transocean reported first-quarter losses of 10 cents per share, which missed the analyst consensus estimate for losses of nine cents. Quarterly revenue clocked in at $906 million, beating the consensus estimate of $885.7 million.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Transocean reported: 
<ul>
<li>Contract drilling revenues for the quarter decreased sequentially by $46 million to $906 million. </li>
<li>Operating and maintenance expense was $618 million, compared with $579 million in the prior quarter. The sequential increase was the result of an unfavorable legal outcome in the first quarter, a favorable legal settlement in the fourth quarter and increased costs related to a rig in shipyard, partially offset by lower in-service maintenance costs across the fleet.</li>
<li>General and administrative expense was $50 million, down from $56 million in the fourth quarter, due primarily to decreased legal and professional fees.</li>
</ul>
&#8220;The Transocean team delivered a solid quarter, with an adjusted EBITDA of $244 million on revenues of $906 million,&#8221; said CEO Jeremy Thigpen. &#8220;We also improved our balance sheet with the repayment of $210 million in outstanding debt.&#8221;
&#8220;While uncertain macroeconomic conditions have resulted in near-term market volatility, including commodity prices, Transocean is very well-positioned to navigate this evolving landscape.&nbsp;In addition to continuing to deliver strong operating performance across our highly contracted fleet, we remain engaged in constructive conversations with our customers on opportunities several years in the future,&#8221; Thigpen added. 
RIG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Transocean stock was up 1.30% after-hours at $2.31 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats

Management

General

ARMN

Aris Mining's Richard Orazietti To Step Down As CFO Following The Completion Of The Company's Q1 2025 Reporting

CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) reported quarterly earnings of $2.56 per share. This is a 115.13 percent increase over earnings of $1.19 per share from the same period last year. The company reported $142.87 million in sales this quarter. This is a 11.91 percent increase over sales of $127.67 million the same period last year.

CVR Partners Q1 EPS $2.56 Up From $1.19 YoY, Sales $142.87M Up From $127.67M YoY

CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.89) by 34.83 percent. This is a 1550 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.31 billion by 25.82 percent. This is a 11.65 percent decrease over sales of $1.86 billion the same period last year.

CVR Energy Q1 Adj. EPS $(0.58) Beats $(0.89) Estimate, Sales $1.65B Beat $1.31B Estimate

Biotech

NGNE

Neurogene To Give Oral Presentation On Monitoring And Treatment To Reverse Rare Complication of High-Dose Gene Therapy At the ASGCT Annual Meeting

Earnings Misses

Waste Management Q1 Adj. EPS $1.67 Beats $1.62 Estimate, Sales $6.02B Miss $6.12B Estimate

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) reported quarterly earnings of $1.29 per share which missed the analyst consensus estimate of $1.30 by 0.77 percent. This is a 13.16 percent increase over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $1.40 billion which met the analyst consensus estimate. This is a 11.61 percent increase over sales of $1.26 billion the same period last year.

Brown & Brown Q1 Adj. EPS $1.29 Misses $1.30 Estimate, Sales $1.40B Inline

Scotiabank analyst Kevin Krishnaratne downgrades Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) from Sector Outperform to Sector Perform and lowers the price target from $17 to $11.

Downgrades

Price Target

Analyst Ratings

LSPD

Scotiabank Downgrades Lightspeed Commerce to Sector Perform, Lowers Price Target to $11

<h3>Gainers</h3>
<ul>
<li>Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) shares moved upwards by 17.6% to $8.55 during Monday's after-market session. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today. </li>
<li>Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares moved upwards by 16.02% to $4.85. The market value of their outstanding shares is at $257.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>SunCar Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) shares moved upwards by 15.38% to $3.0. The company's market cap stands at $325.8 million. As per the news, the FY earnings report came out today. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) stock rose 7.6% to $13.01. The company's market cap stands at $22.4 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock rose 4.99% to $0.27. The market value of their outstanding shares is at $79.3 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock increased by 4.9% to $1.5. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock declined by 12.9% to $0.36 during Monday's after-market session. The company's market cap stands at $28.9 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 10.32% to $0.15. The market value of their outstanding shares is at $7.4 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock declined by 6.31% to $0.57. The market value of their outstanding shares is at $7.9 million. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 5.39% to $0.68. The market value of their outstanding shares is at $4.4 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares declined by 5.27% to $0.0. The market value of their outstanding shares is at $2.8 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock fell 5.23% to $1.05. The company's market cap stands at $42.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BYON

GROV

HOFV

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

WAFU

YOSH

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AVXL

CTMX

CYCC

DBVT

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares increased by 10.0% to $1.1 during Monday's after-market session. The market value of their outstanding shares is at $19.0 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) stock increased by 7.7% to $1.26. The company's market cap stands at $18.8 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares moved upwards by 7.16% to $1.42. The company's market cap stands at $41.3 million. </li>
<li>Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares increased by 4.92% to $0.52. The company's market cap stands at $27.4 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) shares moved upwards by 4.87% to $2.15. The market value of their outstanding shares is at $4.6 million. As per the news, the FY earnings report came out 3 days ago. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares moved upwards by 4.79% to $2.84. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) shares decreased by 7.9% to $3.52 during Monday's after-market session. The company's market cap stands at $87.8 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock declined by 7.37% to $1.51. The market value of their outstanding shares is at $21.1 million. </li>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares decreased by 5.84% to $0.71. The company's market cap stands at $5.3 million. </li>
<li>Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) stock declined by 5.68% to $0.83. The market value of their outstanding shares is at $255.7 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock fell 4.98% to $4.5. The market value of their outstanding shares is at $12.6 million. </li>
<li>Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) stock fell 4.85% to $40.69. The company's market cap stands at $777.6 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZUL

BGLC

ICON

KFRC

OMEX

RMCO

SDST

VCIG

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares moved upwards by 7.3% to $4.12 during Monday's after-market session. The company's market cap stands at $51.7 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares rose 5.88% to $1.26. The market value of their outstanding shares is at $7.7 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock increased by 5.13% to $4.71. The market value of their outstanding shares is at $8.2 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 4.99% to $0.76. The market value of their outstanding shares is at $31.0 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares rose 4.95% to $0.24. The market value of their outstanding shares is at $3.1 million. </li>
<li>Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) stock increased by 4.83% to $2.17. The market value of their outstanding shares is at $97.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock decreased by 12.7% to $1.9 during Monday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares decreased by 8.34% to $74.0. The company's market cap stands at $3.9 billion. As per the press release, Q2 earnings came out today. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) stock declined by 6.62% to $1.27. The market value of their outstanding shares is at $25.2 million. </li>
<li>Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock fell 6.06% to $20.95. The market value of their outstanding shares is at $945.5 million. The company's, Q1 earnings came out today. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares decreased by 5.43% to $0.68. The company's market cap stands at $12.7 million. </li>
<li>908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) stock declined by 4.97% to $5.07. The company's market cap stands at $179.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTZ

MASS

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MOBX

SAGT

SANM

SGMA

TAOP

UCTT

VERI

12 Information Technology Stocks Moving In Monday's After-Market Session

Nucor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s what you need to know <a href="https://www.benzinga.com/pressreleases/25/04/n45053335/nucor-reports-results-for-the-first-quarter-of-2025">from the report</a>.
<ul>
<li>Q1 Revenue: $7.83 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $7.23 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 77 cents, versus estimates of 64 cents</li>
</ul>
Total revenue was down 4% on a year-over-year basis. The steel manufacturer said it shipped approximately 6.83 million tons to outside customers during the quarter. Average sales price per ton decreased&nbsp;12%&nbsp;year-over-year, while total steel mill shipments increased 10% year-over-year.
Nucor repurchased approximately 2.3 million shares at an average price of $133.17 per share in the quarter. The steel company had $806 million remaining on its buyback as of April 5. Nucor ended the quarter with $4.06 billion in cash, cash equivalents and short-term investments on hand.&nbsp;
&#8220;Despite recent financial market volatility, Nucor is seeing solid demand for the steel and steel products we manufacture. Our healthy balance sheet and diverse product portfolio position us well, even in uncertain times,&#8221; said&nbsp;Leon Topalian, chair, president and CEO of Nucor.
See Also: <a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a>
Outlook: Nucor expects second-quarter earnings to increase across all three operating segments (steel mills, steel products and raw materials) compared to the first quarter. 
The stock reaction is somewhat muted, likely due to the company already reporting preliminary results for the quarter in March. Executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 10 a.m. ET.
NUE Price Action: <a href="http://benzinga.com/quote/nue" target="_blank" rel="noreferrer noopener">Nucor shares</a> were up 1.02% after-hours, trading at $117.76 at the time of publication Monday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: saweang.w/Shutterstock.

Guidance

Commodities

Nucor Q1 Earnings: Revenue Beat, EPS Beat, 'Solid' Steel Demand And More

Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Travelzoo to report an earnings per share (EPS) of $0.25.
Investors in Travelzoo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.04, leading to a 10.38% increase in the share price the following trading session.
Here's a look at Travelzoo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.20</td>
<td>0.22</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.26</td>
<td>0.26</td>
<td>0.23</td>
<td>0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874187_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Travelzoo were trading at $13.32 as of April 25. Over the last 52-week period, shares are up 40.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TZOO/earnings">To track all earnings releases for Travelzoo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TZOO

A Peek at Travelzoo's Future Earnings

Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Intrusion will report an earnings per share (EPS) of $-0.11. 
Anticipation surrounds Intrusion's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.15 in the last quarter, leading to a 21.3% drop in the share price on the following day.
Here's a look at Intrusion's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.42</td>
<td>-0.55</td>
<td>-1.20</td>
<td>-2.2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.35</td>
<td>-0.53</td>
<td>-0.94</td>
<td>-1.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-21.0%</td>
<td>-15.0%</td>
<td>19.0%</td>
<td>-26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874178_0.png" alt="eps graph" />
<h3>Performance of Intrusion Shares</h3>
Shares of Intrusion were trading at $1.26 as of April 25. Over the last 52-week period, shares are down 21.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/INTZ/earnings">To track all earnings releases for Intrusion visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Intrusion's Future Earnings

Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Rocky Brands will report an earnings per share (EPS) of $0.52. 
Investors in Rocky Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.03 in the last quarter, leading to a 10.9% drop in the share price on the following day.
Here's a look at Rocky Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.22</td>
<td>0.98</td>
<td>0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.19</td>
<td>0.77</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-27.0%</td>
<td>-2.0%</td>
<td>28.000000000000004%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874157_0.png" alt="eps graph" />
<h3>Tracking Rocky Brands's Stock Performance</h3>
Shares of Rocky Brands were trading at $13.7 as of April 25. Over the last 52-week period, shares are down 47.77%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/RCKY/earnings">To track all earnings releases for Rocky Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCKY

Rocky Brands Earnings Preview

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Zynex to report an earnings per share (EPS) of $-0.24.
The announcement from Zynex is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.11 in the last quarter, leading to a 51.29% drop in the share price on the following day.
Here's a look at Zynex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.06</td>
<td>0.08</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.07</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-51.0%</td>
<td>6.0%</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874149_0.png" alt="eps graph" />
<h3>Zynex Share Price Analysis</h3>
Shares of Zynex were trading at $2.41 as of April 25. Over the last 52-week period, shares are down 79.54%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Zynex</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zynex.
Zynex has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $10.25, the consensus suggests a potential 325.31% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Fractyl Health, Hyperfine and CytoSorbents, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Fractyl Health, with an average 1-year price target of $11.0, suggesting a potential 356.43% upside.</li>
<li>Analysts currently favor an Buy trajectory for Hyperfine, with an average 1-year price target of $1.33, suggesting a potential 44.81% downside.</li>
<li>Analysts currently favor an Buy trajectory for CytoSorbents, with an average 1-year price target of $7.0, suggesting a potential 190.46% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Fractyl Health, Hyperfine and CytoSorbents, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>-2.77%</td>
<td>$35.99M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Fractyl Health</td>
<td>Buy</td>
<td>-57.14%</td>
<td>$3K</td>
<td>-63.42%</td>
</tr>
<tr>
<td>Hyperfine</td>
<td>Buy</td>
<td>-13.59%</td>
<td>$826K</td>
<td>-19.36%</td>
</tr>
<tr>
<td>CytoSorbents</td>
<td>Buy</td>
<td>24.52%</td>
<td>$9.40M</td>
<td>-65.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Zynex ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Zynex is performing well in terms of revenue and profit compared to its peers, but its return on equity is lower in comparison.
<h3>About Zynex</h3>
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
<h3>Financial Milestones: Zynex's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zynex's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.77%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zynex's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.34% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zynex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Zynex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.07, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/ZYXI/earnings">To track all earnings releases for Zynex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZYXI

Earnings Outlook For Zynex

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Stem will report an earnings per share (EPS) of $-0.14. 
The announcement from Stem is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.13, leading to a 13.07% increase in the share price the following trading session.
Here's a look at Stem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.18</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.27</td>
<td>-0.22</td>
<td>-0.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>-22.0%</td>
<td>-41.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874127_0.png" alt="eps graph" />
<h3>Tracking Stem's Stock Performance</h3>
Shares of Stem were trading at $0.4154 as of April 25. Over the last 52-week period, shares are down 77.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STEM/earnings">To track all earnings releases for Stem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STEM

A Preview Of Stem's Earnings

Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Northeast Bank to report an earnings per share (EPS) of $2.78.
The market awaits Northeast Bank's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.17, leading to a 3.03% increase in the share price the following trading session.
Here's a look at Northeast Bank's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.57</td>
<td>1.77</td>
<td>1.79</td>
<td>1.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.74</td>
<td>2.11</td>
<td>1.91</td>
<td>1.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874116_0.png" alt="eps graph" />
<h3>Market Performance of Northeast Bank's Stock</h3>
Shares of Northeast Bank were trading at $91.1 as of April 25. Over the last 52-week period, shares are up 78.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NBN/earnings">To track all earnings releases for Northeast Bank visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Northeast Bank's Earnings Preview

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arhaus, Inc. - ARHS

Arhaus Announces Showroom in Oklahoma City, Oklahoma

Arhaus to Report Third Quarter 2024 Results on November 7, 2024

Arhaus Reports Third Quarter 2024 Results

Arhaus Opens Showroom in Corte Madera, California

Arhaus Raises Fourth Quarter and Full Year 2024 Revenue Outlook

Arhaus Opens Showroom in Winter Park, Florida

Arhaus to Announce Fourth Quarter and Full Year 2024 Results on February 26, 2025

Comments

Arhaus

Arhaus (ARHS) Opciones

Arhaus (NASDAQ:ARHS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL